Century Therapeutics, Inc.
52W $0.39 – $2.94
Century Therapeutics, Inc.
Revenue breakdown: Single Reportable Segment (100%).
Century Therapeutics, Inc. (IPSC) reported significant financial improvement in FY 2025, achieving a net loss of -$9.6M compared to -$126.6M in FY 2024, driven by $109.2M collaboration revenue from the terminated Bristol-Myers Squibb agreement, up from $6.6M. Total operating expenses declined 12% to $126.4M from $144.7M, with R&D at $95.7M (down from $107.2M) and G&A at $24.0M (down from $33.2M),...
Revenue by Segment